Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 7Gynecologic 3Genitourinary 2Gastrointestinal 2Tumor-Agnostic 1Other solid neoplasm 1Head & Neck 1Endocrine 1CNS 1Breast 1

Conditions

Prostatic Neoplasms 1Metastatic Bladder Urothelial Carcinoma 1

Interventions

Magnetic Resonance Spectroscopy 54Specimen Handling 48aldesleukin 35Docetaxel 30Biopsy 28Bevacizumab 24Gemcitabine 21Cyclophosphamide 21Cisplatin 21Radiotherapy 19Prednisone 17Sorafenib 16Carboplatin 16sargramostim 15PROSTVAC 15Paclitaxel 14Interferon-alpha 14Sunitinib 13ixabepilone 12cabozantinib 12Immunoglobulin G 12Goserelin 12Disulfides 12fludarabine phosphate 11fludarabine 11Nivolumab 11Fluorouracil 11Chemotherapy, Adjuvant 11pembrolizumab 10bicalutamide 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × berzosertib × Genitourinary × Clear all
NCT03517969 2026-04-23

M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
73 enrolled 14 charts
Genitourinary

Prostatic Neoplasms

NCT02567409 2025-03-03

Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer

National Cancer Institute (NCI)

Phase 2 Completed
87 enrolled 13 charts
Genitourinary

Metastatic Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡